Cai (NIH Bethesda) provided LRRK2-/- mice
Cai (NIH Bethesda) provided LRRK2-/- mice. LRRK2 kinase inhibitors; however, poor consensus on physiological LRRK2 substrates has hampered clinical development of such therapeutics. We employ… Read More »Cai (NIH Bethesda) provided LRRK2-/- mice